Dna X (SONM) Cost of Revenue (2018 - 2025)

Dna X has reported Cost of Revenue for 8 years, with the latest figure at $14.4 million in Q3 2025.

• For the quarter ending Q3 2025, Cost of Revenue rose 33.44% year-over-year to $14.4 million; the trailing twelve-month figure through Sep 2025 stood at $60.7 million (down 40.37% YoY), and the FY2024 full-year result was $48.4 million, down 34.9% from the prior year.
• Cost of Revenue for Q3 2025 stood at $14.4 million, up from $3.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $68.6 million in Q4 2023, with the low at -$22.2 million in Q4 2021.
• Historically, Cost of Revenue has averaged $11.2 million across 5 years, with a median of $8.5 million in 2024.
• Annual changes were most pronounced in 2022 — Cost of Revenue slumped 77.71% — and 2023, when it jumped 4412.57%.
• Dna X's Cost of Revenue stood at -$22.2 million in 2021, then soared by 106.86% to $1.5 million in 2022, then jumped by 4412.57% to $68.6 million in 2023, then plunged by 42.23% to $39.6 million in 2024, then plunged by 63.66% to $14.4 million in 2025.
• The last three Cost of Revenue figures came in at $14.4 million (Q3 2025), $3.4 million (Q2 2025), and $3.2 million (Q1 2025), per Business Quant data.